Introduction:
Renal cell carcinoma (RCC) is the sixth most common cancer in men and the tenth most common cancer in women. RCC is the thirteenth leading cause of cancer-related mortality worldwide. There are many significant prognostic determinants that are important to the management of RCC. One of the them are tumor microenvironment associated biomarkers. Tumor microenvironment (TME) exhibits either tumor suppressive or tumor-promoting effects. Immune cells are important constituents of the TME. CD8 tumor infiltrating lymphocytes are related to prognosis of many tumors. Tumor associated macrophages (TAMs) are important immune populations that are usually of the M2 type which are related to tumor invasion, growth and metastasis. PD-L1 is one of the immune checkpoints that inhibits T-cell function leading to tumor growth and proliferation. PD-L1 can be used as predictive marker for tumor aggressiveness.

Aim of the work:
The current study was carried out to study the immuno-histochemical (IHC) expression of CD8, CD163 and PD-L1 in clear cell renal cell carcinoma and to correlate their expression with different clinic-pathologic parameters of the tumor.